Ian McFadden

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 8

Top Topics

Multiple Myeloma

Chronic Kidney Disease

Top Venues

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Ortiol, Phillipe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios- Athanasios Dimopoulos
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & lymphoma (2024)
Carl Ola Landgren, Thomas J Prior, Tara Masterson, Christoph Heuck, Orlando F Bueno, Ajeeta B Dash, Hermann Einsele, Hartmut Goldschmidt, Stefan Knop, Cong Li, Ulf-Henrik Mellqvist, Ian McFadden, Corina Oprea, Jeremy A Ross, Mihaela Talpes, Jay R Hydren, Jennifer M Ahlstrom, Dickran Kazandjian, Niels Weinhold, Rick Zhang, Maryalice Stetler-Stevenson, Gerald Marti, Sean M Devlin
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood 144 (4) (2024)
Carl Ola Landgren, Thomas J Prior, Tara Masterson, Christoph Heuck, Orlando F Bueno, Ajeeta B Dash, Hermann Einsele, Hartmut Goldschmidt, Stefan Knop, Cong Li, Ulf-Henrik Mellqvist, Ian McFadden, Corina Oprea, Jeremy A Ross, Mihaela Talpes, Jay R Hydren, Jennifer M Ahlstrom, Dickran Kazandjian, Niels Weinhold, Rick Zhang, Maryalice Stetler-Stevenson, Gerald Marti, Sean M Devlin
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood 144 (4) (2024)
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Ortiol, Phillipe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios- Athanasios Dimopoulos
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & lymphoma (2024)
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Ortiol, Phillipe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios- Athanasios Dimopoulos
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & lymphoma 65 (6) (2024)
Carl Ola Landgren, Thomas J Prior, Tara Masterson, Christoph Heuck, Orlando F Bueno, Ajeeta B Dash, Hermann Einsele, Hartmut Goldschmidt, Stefan Knop, Cong Li, Ulf-Henrik Mellqvist, Ian McFadden, Corina Oprea, Jeremy A Ross, Mihaela Talpes, Jay R Hydren, Jenny Ahlstrom, Dickran Kazandjian, Niels Weinhold, Rick Zhang, Maryalice Stetler-Stevenson, Gerald E Marti, Sean M Devlin
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma. Blood (2024)
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Ortiol, Phillipe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios- Athanasios Dimopoulos
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & lymphoma 65 (6) (2024)
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Ortiol, Phillipe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios- Athanasios Dimopoulos
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & lymphoma 65 (6) (2024)